We applied a simplified method using polymerase chain reaction (PCR)-based enzymatic digestion for the detection of epidermal growth factor receptor (EGFR) mutation. Materials and Methods: We selected 74 samples of adenocarcinoma of the lung with EGFR exons 19 and 21 that had been previously sequenced. We designed PCR primers and chose a DNA restriction enzyme. Seventy four additional lung cancer samples were tested as a test set. For test sets, the PCR-based method was performed first, followed by validation of the result by DNA sequencing. Results: In the first sample group, we found 15 (20.3%) mutations in exon 19, and 9 (12.2%) mutations in exon 21 using the sequencing method. By using the PCR-based method, we were able to identify all of the mutated samples detected by the sequencing method. The PCR-based method also detected mutations in exon 19 in three additional samples and in exon 21 in one additional sample. In the second sample group, by performing the PCR-based method, we found 10 (13.5%) and 7 (9.5%) mutations in exons 19 and 21, respectively. Additional mutations in exon 19 were identified in 2 samples by the sequencing method. However, the sequencing method failed to identify a mutation in exon 21 in one sample. Conclusion: The sensitivity of the PCR-based enzymatic digestion method seems to be comparable to that of the traditional sequencing method for detecting EGFR mutations. Our method can be widely used as a screening test to select patients who may benefit from EGFR targeted therapy. (J Lung Cancer 2012;11(2):77 83)
INTRODUCTION
Among the various molecular targeted therapeutic drugs, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is one of the most important agents for the treatment of non-small cell lung cancer (NSCLC) (1) . Not all patients, however, respond to EGFR TKIs. Since only a 78 J Lung Cancer 2012;11 (2) :77-83 subgroup of patients with NSCLC experience a clinical benefit from treatment with EGFR inhibitors, the identification of the patients who are most likely to respond to these drugs is very important. Clinical features have been known to be the most important parameters for such prediction. Clinical studies of gefitinib or erlotinib in NSCLC suggest that patients that are most likely to have a positive clinical response to anti-EGFR therapy (1) (2) (3) are non-smoking Asian, females with tumors that have histologic features of adenocarcinoma. The subsequent discovery that somatic mutations within the tyrosine kinase of the EGFR gene that are associated with a response to EGFR TKIs in NSCLC suggest that the selection of patients through molecular screening might be feasible (4, 5) . Publications have documented various mutations of EGFR genes. Approximately 90% of EGFR mutations affect small regions of exons 18 to 24 that code for the EGFR tyrosine kinase domain. Among them, the most common mutations are in-frame deletion in exon 19 around the codons 746 to 750, and a missense mutation leading to a substitution of arginine for leucine at codon 858 (L858R) in exon 21 (6) . Therefore, mutations of the EGFR gene in exons 19 and 21 may be useful molecular markers for predicting a good response to EGFR TKIs in NSCLC.
At the present time, the most common method to detect such mutations is the direct sequencing of DNA that has been isolated from tumor cells. However, this method is complicated and time-consuming, limiting its wide use for screening purposes. Also, there are regions in the world where the sequencing method is not available. We have designed a simplified method using polymerase chain reaction (PCR)-based enzymatic digestion for the detection of mutations in exons 19 and 21, and have validated its usefulness as an initial screening tool.
MATERIALS AND METHODS

1) Sample selection
Among the patients who underwent surgical resection for primary lung cancer between December 2000 and May 2006
at Seoul National University Hospital, we selected 148 patients whose frozen specimens were available from our Lung Cancer Tissue Bank.
Informed consent for tissue collection and gene analyses for research purposes was obtained from individual patients pre-operatively, according to the policy of the Lung Cancer Tissue Bank at The Cancer Research Institute of Seoul National University. We also followed the recommendations of the Declaration of Helsinki for biomedical research involving human subjects. The study protocol, as well as ethical issues, were reviewed and approved by Seoul National University Hospital IRB (H-0504/147-016).
2) Tissue sample collection and DNA extraction
Tissue sampling was performed immediately after lung resection, and a gross dissection of tumor tissue was performed.
The samples were quickly frozen in liquid nitrogen and stored at −80 o C until the analysis. Genomic DNA samples from the frozen lung cancer tissue were isolated by using the QIAmp tissue kit (Qiagen, Hilden, Germany), according to manufacturer's protocol.
3) PCR amplification and direct sequencing
For EGFR mutations, 10 ng of DNA were amplified in a 20μL reaction solution, containing 2μL of 10× buffer In-frame deletion 2233∼2247 del AAGGAATTAAGAGAA K745∼E749 del
In-frame insertion 2321∼2326 ins CCCACG A772∼H773 ins 1 (1.4) 21
Single-nucleotide substitution 2573T＞G L858R 9 (12.2)
EGFR: epidermal growth factor receptor, del: deletion, ins: insertion. 
4) PCR-based and enzymatic digestion method
Based on the initial EGFR sequencing result (Table 1) for 74 patients, we designed PCR primers with the capability to detect mutations without sequencing. For exon 19, we selected primers encompassing the commonly deleted sequences and the resulting size of PCR products for the wild type to be 157 bp.
The correct size of the amplified PCR products was checked by electrophoresis on 3.5% metaphor agarose gel. If there was a deletion in exon 19, two bands, one band 157 bp in size and the other smaller, were observed. If there was no mutation, only a single band of 157 bp was observed ( 
5) Comparison of two methods
First, we selected 74 samples of adenocarcinoma whose EGFR: epidermal growth factor receptor, PCR: polymerase chain reaction, del: deletion. The gold standard was presumed by the final result obtained from re-testing of the sequencing method.
RESULTS
1) The training sample group
EGFR mutations were detected in 26 patients in the first set of 74 samples. Among these samples, using the sequencing method, we found 15 (20.3%) mutations in exon 19, and 9 (12.2%) mutations in exon 21. All mutations of exon 19 were deletion mutations, and the mutations in exon 21 were L858R substitution mutations (Table 1) .
By using the PCR-based method, we were able to identify all the mutated samples detected by the sequencing method. At the same time, we were able to detect mutations in exon 19
in three samples, and in exon 21 in one additional sample which were not detected in initial Sanger sequence method.
Those additional samples were confirmed by performing a repeated sequencing analysis ( Table 2) .
2) The test sample group
In the second set of samples, the PCR-based method was performed first. It detected 10 (13.5%) and 7 (9.5%) mutations in exons 19 and 21, respectively. Additional mutations in exon 19 were identified in 2 samples by the sequencing method.
However, the sequencing method failed to identify a mutation in exon 21 in one sample ( Table 3) .
3) Sensitivity of two methods
When we compared the two methods, the sensitivity of the sequencing method for exon 19 mutation was 90%, whereas that of the PCR-base method was 93%. The two methods were not statistically different (McNemar test). For exon 21, the sequencing method had a sensitivity of 88% and the PCR-based method showed 100% sensitivity.
DISCUSSION AND CONCLUSION
Since the initial identification of a close correlation between EGFR mutations and radiographic regression in NSCLC pa- were detected with direct sequencing. These two samples were re-tested with both methods and the result was the same. There are several possible explanations. As both methods were performed using the same DNA extracted at one time, the difference of concentration of DNA cannot explain the result.
We believe that the two false-negative results can be attributed to an error during the gel running. Both samples possessed 9 bp deletion, which was the smallest deletion in our series. In the literature, 5 base pair deletion mutation has been reported as the smallest mutation in exon 19. We re-tested two false negative samples using a higher density agarose gel and were able to identify a faint band underneath the wild type DNA band (Fig. 2) . As a consequence, we presumed that the reason of false negative was due to the difference in size between the mutated and wild-type DNA was too small to be differentiated on the 3.5% agarose gel. The detection of such small size differences may require either a different electrophoresis running protocol on the higher concentration of agarose/polymer gel or the use of capillary electrophoresis (7) .
Another possible explanation is an intrinsic low sensitivity of our method. As shown in Fig. 2 method detected only 25 cases (7) . Our method is similar to other PCR-based methods in that we use PCR reactions for the amplification and restriction of endonuclease for the detection of mutations. The difference between these methods and ours were identified by applying mutant-enriched PCR assay for surgical specimens, as well as cytology or biopsy specimens.
We had applied mutant enrichment methods for these two false negative samples. However, the band was too strong to discriminate a small 9 bp deletion mutation from the wild DNA in exon 19. Based on our result, we believe it may not be necessary to apply the time-consuming mutant-enrichment method for the freshly frozen, well prepared surgical specimen for the screening purpose of EGFR mutation. For the most part, it is not yet known whether or not these low-abundance mutations will ultimately have predictive or prognostic significance.
Although these methods are of great value, in terms of improved sensitivity and accuracy, because of limited resources and expertise, most institutions will find routine screening for mutations with these methods to be a major challenge and costly to implement.
Infrequent mutations or new mutations are not detectable using our method. Although many EGFR mutations have been reported, not all have been responsive to EGFR TKIs. The two most common EGFR mutations that have been identified, representing 85% to 90% of EGFR mutations, consist of either a deletion in exon 19 of a leucine-arginine-glutamic acid-alanine or a leucine-to-arginine substitution at position 858 (L858R) (16) . These mutations occur near the ATP cleft of the tyrosine kinase domain, where 4-anilinoquinazoline compounds, such as gefitinib, compete with ATP for binding (4, 5, (17) (18) (19) .
Consequently, EGFR mutations in exons 19 and 21 may be useful molecular markers for treatment of NSCLC. In our own series of the Korean population, EGFR mutations on these two loci were found in 32.4% of adenocarcinoma patients and were 92.3% of the entire EGFR mutations found (20) . This means that we can identify a majority of patients likely to respond to EGFR TKI by detecting mutations in exons 19 and 21. In our first set, the PCR-based method found 4 additional mutations, compared to that of direct sequencing. Thus, the falsenegative rate for direct sequencing was 14.3% (4/28).
Compared to direct sequencing, our method can be performed more easily with less cost, and can still achieve superior sensitivity. If our tests are negative, direct sequencing of EGFR exons 18 and 20 can be performed to detect the remaining 10% of EGFR mutations. EGFR mutation screening is currently not routinely recommended in patient management. However, it is possible that testing of tumor tissue for EGFR mutations may soon be indicated in all patients with adenocarcinoma of the lung to aid in selecting therapy in various neoadjuvant, adjuvant, or palliative settings. In western countries, at least 10% of lung adenocarcinomas will harbor EGFR mutations. In Korea and other Asian countries, 30∼35% of adenocarcinomas are expected to have EGFR mutations, and 20∼25% of these will be detectable using our methods. Our method is simple and easy to set up, requiring only an ordinary laboratory where PCR reaction can be performed. Hence, our PCR-based enzymatic digestion method can be used as an initial screening test in virtually every institution.
In conclusion, for well-prepared freshly frozen tumor samples, our conventional PCR-based method could detect EGFR mutations in exons 19 and 21 without more expensive and time-consuming techniques, and can be used as an initial screening test for the selection of potential candidates of EGFR TKI.
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